Clinical overview of MDM2/X-targeted therapies

Frontiers in Oncology

Volumn 6, Issue JAN, 2016, Pages

  Burgess, Andrew ^a,b   Chia, Kee Ming ^a   Haupt, Sue ^c   Thomas, David ^a,b   Haupt, Ygal ^c   Lim, Elgene ^a,b  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Cancer therapy; MDM2; MDMX; Nutlin; P53

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DABRAFENIB; GROWTH DIFFERENTIATION FACTOR 15; HEAT SHOCK PROTEIN 90; NUTLIN 3; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P21; PROTEIN P53; RIBOCICLIB; TRAMETINIB; [2 (4 TERT BUTYL 2 ETHOXYPHENYL) 4,5 BIS(4 CHLOROPHENYL) 4,5 DIHYDRO 4,5 DIMETHYL 1H IMIDAZOL 1 YL][4 [3 (METHYLSULFONYL)PROPYL] 1 PIPERAZINYL]METHANONE;

APOPTOSIS; CANCER THERAPY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELLULAR STRESS RESPONSE; CHROMATIN STRUCTURE; CLINICAL TRIAL (TOPIC); DNA REPAIR; DRUG TARGETING; GENE ACTIVATION; GENE AMPLIFICATION; GENE MUTATION; HUMAN; LEUKEMIA; LIPOMA; NEUTROPENIA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; SHORT SURVEY; THROMBOCYTOPENIA; UBIQUITINATION;

EID: 84958152593     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2016.00007     Document Type: Short Survey

References (64)

1. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, et al. Restoration of p53 function leads to tumour regression in vivo. Nature (2007) 445:661-5. doi:10.1038/nature05541
2. Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell (2006) 127:1323-34. doi:10.1016/j.cell.2006.12.007
3. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature (2007) 445:656-60. doi:10.1038/nature05529
4. Bykov VJN, Wiman KG. Mutant p53 reactivation by small molecules makes its way to the clinic. FEBS Lett (2014) 588:2622-7. doi:10.1016/j.febslet.2014.04.017
5. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal (2013) 6:l1. doi:10.1126/scisignal.2004088
6. Pant V, Lozano G. Limiting the power of p53 through the ubiquitin proteasome pathway. Genes Dev (2014) 28:1739-51. doi:10.1101/gad.247452.114
7. Tsvetkov P, Reuven N, Shaul Y. Ubiquitin-independent p53 proteasomal degradation. Cell Death Differ (2009) 17:103-8. doi:10.1038/cdd.2009.67
8. Meek DW, Anderson CW. Posttranslational modification of p53: cooperative integrators of function. Cold Spring Harb Perspect Biol (2009) 1:a000950. doi:10.1101/cshperspect.a000950
9. Brooks CL, Gu W. p53 regulation by ubiquitin. FEBS Lett (2011) 585:2803-9. doi:10.1016/j.febslet.2011.05.022
10. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature (1997) 387:299-303. doi:10.1038/387299a0
11. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature (1997) 387:296-9. doi:10.1038/387296a0
12. Li M, Brooks CL, Wu-Baer F, Chen D, Baer R, Gu W. Mono-versus polyubiquitination: differential control of p53 fate by Mdm2. Science (2003) 302:1972-5. doi:10.1126/science.1091362
13. Leslie PL, Ke H, Zhang Y. The MDM2 RING domain and central acidic domain play distinct roles in MDM2 protein homodimerization and MDM2-MDMX protein heterodimerization. J Biol Chem (2015) 290:12941-50. doi:10.1074/jbc. M115.644435
14. Brooks CL, Gu W. p53 ubiquitination: Mdm2 and beyond. Mol Cell (2006) 21:307-15. doi:10.1016/j.molcel.2006.01.020
15. Shadfan M, Lopez-Pajares V, Yuan Z-M. MDM2 and MDMX: alone and together in regulation of p53. Transl Cancer Res (2012) 1:88-9.
16. Mao L, Merlo A, Bedi G, Shapiro GI, Edwards CD, Rollins BJ, et al. A novel p16INK4A transcript. Cancer Res (1995) 55:2995-7.
17. Stone S, Jiang P, Dayananth P, Tavtigian SV, Katcher H, Parry D, et al. Complex structure and regulation of the P16 (MTS1) locus. Cancer Res (1995) 55:2988-94.
18. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, et al. The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2. EMBO J (1998) 17:5001-14. doi:10.1093/emboj/17.17.5001
19. Honda R, Yasuda H. Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J (1999) 18:22-7. doi:10.1093/emboj/18.1.22
20. Lohrum MA, Ashcroft M, Kubbutat MH, Vousden KH. Contribution of two independent MDM2-binding domains in p14(ARF) to p53 stabilization. Curr Biol (2000) 10:539-42. doi:10.1016/S0960-9822(00)00472-3
21. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 303:844-8. doi:10.1126/science.1092472
22. Patton JT, Mayo LD, Singhi AD, Gudkov AV, Stark GR, Jackson MW. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res (2006) 66:3169-76. doi:10.1158/0008-5472.CAN-05-3832
23. Hu B, Gilkes DM, Farooqi B, Sebti SM, Chen J. MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. J Biol Chem (2006) 281:33030-5. doi:10.1074/jbc. C600147200
24. Wade M, Wong ET, Tang M, Stommel JM, Wahl GM. Hdmx modulates the outcome of p53 activation in human tumor cells. J Biol Chem (2006) 281:33036-44. doi:10.1074/jbc. M605405200
25. Reed D, Shen Y, Shelat AA, Arnold LA, Ferreira AM, Zhu F, et al. Identification and characterization of the first small molecule inhibitor of MDMX. J Biol Chem (2010) 285:10786-96. doi:10.1074/jbc. M109.056747
26. Popowicz GM, Czarna A, Wolf S, Wang K, Wang W, Dömling A, et al. Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery. Cell Cycle (2010) 9:1104-11. doi:10.4161/cc.9.6.10956
27. Herman AG, Hayano M, Poyurovsky MV, Shimada K, Skouta R, Prives C, et al. Discovery of Mdm2-MdmX E3 ligase inhibitors using a cell-based ubiquitination assay. Cancer Discov (2011) 1:312-25. doi:10.1158/2159-8290.CD-11-0104
28. Pellegrino M, Mancini F, Lucà R, Coletti A, Giacchè N, Manni I, et al. Targeting the MDM2/MDM4 interaction interface as a promising approach for p53 reactivation therapy. Cancer Res (2015) 75:4560-72. doi:10.1158/0008-5472.CAN-15-0439
29. Huang M, Zhang H, Liu T, Tian D, Gu L, Zhou M. Triptolide inhibits MDM2 and induces apoptosis in acute lymphoblastic leukemia cells through a p53-independent pathway. Mol Cancer Ther (2013) 12:184-94. doi:10.1158/1535-7163.MCT-12-0425
30. Qin J-J, Wang W, Voruganti S, Wang H, Zhang W-D, Zhang R. Inhibiting NFAT1 for breast cancer therapy: new insights into the mechanism of action of MDM2 inhibitor JapA. Oncotarget (2015) 6:33106-19. doi:10.18632/oncotarget.5851
31. Wang H, Ma X, Ren S, Buolamwini JK, Yan C. A small-molecule inhibitor of MDMX activates p53 and induces apoptosis. Mol Cancer Ther (2011) 10:69-79. doi:10.1158/1535-7163.MCT-10-0581
32. Seo S-K, Hwang C-S, Choe T-B, Hong S-I, Yi JY, Hwang S-G, et al. Selective inhibition of histone deacetylase 2 induces p53-dependent survivin downregulation through MDM2 proteasomal degradation. Oncotarget (2015) 6:26528-40. doi:10.18632/oncotarget.3100
33. Zhang H, Gu L, Liu T, Chiang K-Y, Zhou M. Inhibition of MDM2 by nilotinib contributes to cytotoxicity in both Philadelphia-positive and negative acute lymphoblastic leukemia. PLoS One (2014) 9:e100960. doi:10.1371/journal.pone.0100960
34. Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LGGC, Masucci M, et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med (2004) 10:1321-8. doi:10.1038/nm1146
35. Zhang X-P, Liu F, Wang W. Two-phase dynamics of p53 in the DNA damage response. Proc Natl Acad Sci U S A (2011) 108:8990-5. doi:10.1073/pnas.1100600108
36. Reisman D, Takahashi P, Polson A, Boggs K. Transcriptional regulation of the p53 tumor suppressor gene in S-phase of the cell-cycle and the cellular response to DNA damage. Biochem Res Int (2012) 2012:808934-5. doi:10.1155/2012/808934
37. Fischer M, Quaas M, Steiner L, Engeland K. The p53-p21-DREAM-CDE/CHR pathway regulates G2/M cell cycle genes. Nucleic Acids Res (2016) 44(1):164-74. doi:10.1093/nar/gkv927
38. Andreassen PR, Lohez OD, Lacroix FB, Margolis RL. Tetraploid state induces p53-dependent arrest of nontransformed mammalian cells in G1. Mol Biol Cell (2001) 12:1315-28. doi:10.1091/mbc.12.5.1315
39. Thompson SL, Compton DA. Proliferation of aneuploid human cells is limited by a p53-dependent mechanism. J Cell Biol (2010) 188:369-81. doi:10.1083/jcb.200905057
40. Kuribayashi K, Finnberg N, Jeffers JR, Zambetti GP, El-Deiry WS. The relative contribution of pro-apoptotic p53-target genes in the triggering of apoptosis following DNA damage in vitro and in vivo. Cell Cycle (2011) 10:2380-9. doi:10.4161/cc.10.14.16588
41. Haupt S, Berger M, Goldberg Z, Haupt Y. Apoptosis-the p53 network. J Cell Sci (2003) 116:4077-85. doi:10.1242/jcs.00739
42. Kracikova M, Akiri G, George A, Sachidanandam R, Aaronson SA. A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis. Cell Death Differ (2013) 20:576-88. doi:10.1038/cdd.2012.155
43. Khoo KH, Hoe KK, Verma CS, Lane DP. Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov (2014) 13:217-36. doi:10.1038/nrd4236
44. Tovar C, Graves B, Packman K, Filipovic Z, Higgins B, Xia M, et al. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models. Cancer Res (2013) 73:2587-97. doi:10.1158/0008-5472.CAN-12-2807
45. Ray-Coquard I, Blay J-Y, Italiano A, Le Cesne A, Penel N, Zhi J, et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol (2012) 13:1133-40. doi:10.1016/S1470-2045(12)70474-6
46. AndreeffM, Kelly KR, Yee KW, Assouline SE, Strair R, Popplewell L, et al. Results of the phase 1 trial of RG7112, a small-molecule MDM2 antagonist in leukemia. Clin Cancer Res (2015). doi:10.1158/1078-0432.CCR-15-0481
47. Yeudall WA, Vaughan CA, Miyazaki H, Ramamoorthy M, Choi M-Y, Chapman CG, et al. Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration. Carcinogenesis (2012) 33:442-51. doi:10.1093/carcin/bgr270
48. Ludwig RL, Bates S, Vousden KH. Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol Cell Biol (1996) 16:4952-60. doi:10.1128/MCB.16.9.4952
49. Dong P, Karaayvaz M, Jia N, Kaneuchi M, Hamada J, Watari H, et al. Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis. Oncogene (2013) 32:3286-95. doi:10.1038/onc.2012.334
50. Zhou G, Wang J, Zhao M, Xie T-X, Tanaka N, Sano D, et al. Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation. Mol Cell (2014) 54:960-74. doi:10.1016/j.molcel.2014.04.024
51. Zhu J, Sammons MA, Donahue G, Dou Z, Vedadi M, Getlik M, et al. Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. Nature (2015) 525:206-11. doi:10.1038/nature15251
52. Fiorini C, Cordani M, Padroni C, Blandino G, Di Agostino S, Donadelli M. Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine. Biochim Biophys Acta (2015) 1853:89-100. doi:10.1016/j.bbamcr.2014.10.003
53. Chee JLY, Saidin S, Lane DP, Leong SM, Noll JE, Neilsen PM, et al. Wild-type and mutant p53 mediate cisplatin resistance through interaction and inhibition of active caspase-9. Cell Cycle (2013) 12:278-88. doi:10.4161/cc.23054
54. Zhang S, Zhou L, Hong B, Van Den Heuvel APJ, Prabhu VV, Warfel NA, et al. Small-molecule NSC59984 restores p53 pathway signaling and antitumor effects against colorectal cancer via p73 activation and degradation of mutant p53. Cancer Res (2015) 75:3842-52. doi:10.1158/0008-5472.CAN-13-1079
55. Mello SS, Attardi LD. Not all p53 gain-of-function mutants are created equal. Cell Death Differ (2013) 20:855-7. doi:10.1038/cdd.2013.53
56. Aziz MH, Shen H, Maki CG. Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3. Oncogene (2011) 30:4678-86. doi:10.1038/onc.2011.185
57. Francoz S, Froment P, Bogaerts S, De Clercq S, Maetens M, Doumont G, et al. Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc Natl Acad Sci U S A (2006) 103:3232-7. doi:10.1073/pnas.0508476103
58. Wade M, Li Y-C, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer (2013) 13:83-96. doi:10.1038/nrc3430
59. Rao B, Lain S, Thompson AM. p53-based cyclotherapy: exploiting the "guardian of the genome" to protect normal cells from cytotoxic therapy. Br J Cancer (2013) 109:2954-8. doi:10.1038/bjc.2013.702
60. Carrillo AM, Hicks M, Khabele D, Eischen CM. Pharmacologically increasing Mdm2 inhibits DNA repair and cooperates with genotoxic agents to kill p53-inactivated ovarian cancer cells. Mol Cancer Res (2015) 13:1197-205. doi:10.1158/1541-7786.MCR-15-0089
61. Bailey ST, Shin H, Westerling T, Liu XS, Brown M. Estrogen receptor prevents p53-dependent apoptosis in breast cancer. Proc Natl Acad Sci U S A (2012) 109:18060-5. doi:10.1073/pnas.1018858109
62. Jeay S, Gaulis S, Ferretti S, Bitter H, Ito M, Valat T, et al. A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097. Elife (2015) 4:12985. doi:10.7554/eLife.06498
63. Sonkin D. Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors. Elife (2015) 4:e10279. doi:10.7554/eLife.10279
64. Saiki AY, Caenepeel S, Cosgrove E, Su C, Boedigheimer M, Oliner JD. Identifying the determinants of response to MDM2 inhibition. Oncotarget (2015) 6:7701-12. doi:10.18632/oncotarget.3116